|
Cancer cachexia syndrome in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a single-institution, prospective, observational study. |
|
|
Employment - Vifor Pharma (I) |
Consulting or Advisory Role - MSD; Roche |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Genesis Pharmaceuticals; Roche |
|
|
Travel, Accommodations, Expenses - Astellas Pharma; MSD; Teva |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Alexandros-Pantelis Tsigkas |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |